Bavarian Nordic announces commercial availability of mpox vaccine in US
Pharmaceutical Business Review
APRIL 3, 2024
In October 2023, the CDC’s Advisory Committee on Immunization Practices (ACIP) unanimously voted to update these recommendations, endorsing JYNNEOS for routine use in individuals aged 18 and older with specific risk factors. The CDC estimates that two million individuals in the US are eligible for the mpox vaccination.
52 
Let's personalize your content